Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 5
2011 2
2012 1
2013 2
2014 4
2015 5
2016 4
2017 18
2018 27
2019 30
2020 28
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

118 results
Results by year
Filters applied: . Clear all
Page 1
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. Lancet JE, et al. J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19. J Clin Oncol. 2018. PMID: 30024784 Free PMC article. Clinical Trial.
Conclusion CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy....
Conclusion CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults w …
CPX-351 (vyxeos) in AML.
Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. Alfayez M, et al. Leuk Lymphoma. 2020 Feb;61(2):288-297. doi: 10.1080/10428194.2019.1660970. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31547736
In this study CPX-351 had a higher median OS than 7 + 3 (9.56 vs 5.95 months, HR 0.69; 95% CI: 0.52 to 0.90, p = 0.005). In this profile, we review preclinical and clinical data, and discuss limitations and future directions with CPX-351 use in AML....
In this study CPX-351 had a higher median OS than 7 + 3 (9.56 vs 5.95 months, HR 0.69; 95% CI: 0.52 to 0.90, p = 0.005). In th …
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD, Tardi P, Louie AC. Mayer LD, et al. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31213803 Free PMC article. Review.
The notable clinical efficacy of CPX-351 is achieved through maintenance of a synergistic 5:1 molar ratio of cytarabine and daunorubicin within the liposome after intravenous injection. ...Thus, the CPX-351 liposome protects cytarabine and daunorubicin …
The notable clinical efficacy of CPX-351 is achieved through maintenance of a synergistic 5:1 molar ratio of cytarabine and da …
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. Kolitz JE, et al. Leuk Lymphoma. 2020 Mar;61(3):631-640. doi: 10.1080/10428194.2019.1688320. Epub 2019 Nov 25. Leuk Lymphoma. 2020. PMID: 31760835
CPX-351 is a dual-drug liposomal encapsulation of cytarabine/daunorubicin. ...The safety profile of CPX-351 consolidation was consistent with that of the overall study. ...
CPX-351 is a dual-drug liposomal encapsulation of cytarabine/daunorubicin. ...The safety profile of CPX-351 cons
CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, Simonetti G, Martinelli G, Cerchione C. Cafaro A, et al. Minerva Med. 2020 Oct;111(5):455-466. doi: 10.23736/S0026-4806.20.07017-2. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955826 Free article. Review.
CPX-351 did show improvements of overall survival compared to traditional "7+3" in newly diagnosed secondary and therapy-related AML in adult patients. ...In summary, CPX-351 offers finally something new in the landscape of AML therapy. ...
CPX-351 did show improvements of overall survival compared to traditional "7+3" in newly diagnosed secondary and therapy-relat
CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C, Lancet JE. Talati C, et al. Future Oncol. 2018 May;14(12):1147-1154. doi: 10.2217/fon-2017-0603. Epub 2018 Jan 30. Future Oncol. 2018. PMID: 29378418 Review.
Therapeutic options mainly consist of hypomethylating agents, ongoing clinical trials and, less commonly, intensive cytotoxic chemotherapy. CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising …
Therapeutic options mainly consist of hypomethylating agents, ongoing clinical trials and, less commonly, intensive cytotoxic chemotherapy. …
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA. Cooper TM, et al. J Clin Oncol. 2020 Jul 1;38(19):2170-2177. doi: 10.1200/JCO.19.03306. Epub 2020 May 13. J Clin Oncol. 2020. PMID: 32401633 Clinical Trial.
PURPOSE: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. ...Hematopoietic stem cell transplantation (HSCT) was used as consolida …
PURPOSE: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX
CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Brunetti C, Anelli L, Zagaria A, Specchia G, Albano F. Brunetti C, et al. Expert Rev Hematol. 2017 Oct;10(10):853-862. doi: 10.1080/17474086.2017.1369400. Epub 2017 Aug 24. Expert Rev Hematol. 2017. PMID: 28814164 Review.
Areas covered: Preliminary results from an ongoing phase III clinical trial suggest that CPX-351 could represent an interesting treatment option in both induction and 'bridge-to-transplant' settings. ...Herein, we detail the main pharmacological features of CPX
Areas covered: Preliminary results from an ongoing phase III clinical trial suggest that CPX-351 could represent an interestin …
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.
Vincelette ND, Ding H, Huehls AM, Flatten KS, Kelly RL, Kohorst MA, Webster J, Hess AD, Pratz KW, Karnitz LM, Kaufmann SH. Vincelette ND, et al. Sci Rep. 2019 Mar 5;9(1):3617. doi: 10.1038/s41598-019-40218-0. Sci Rep. 2019. PMID: 30837643 Free PMC article.
Conversely, CHK1 inhibition diminishes the cell cycle effects of CPX-351. Moreover, CHK1 knockdown or addition of a CHK1 inhibitor such as MK-8776, rabusertib or prexasertib enhances CPX-351-induced apoptosis in multiple TP53-null and TP53-wildtype AML …
Conversely, CHK1 inhibition diminishes the cell cycle effects of CPX-351. Moreover, CHK1 knockdown or addition of a CHK1 inhib …
118 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page